English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/213397
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Early emergence of opportunistic infections after starting direct‐acting antiviral drugs in HIV/HCV‐coinfected patients

AuthorsMacias, Juan; Téllez, Francisco; Rivero-Juárez, Antonio; Palacios, Rosario; Morano-Amado, Luis E.; Merino, Dolores; Collado, Antonio; García-Fraile Fraile, L. J.; Omar, Mohamed; Pineda, Juan A.
KeywordsDirect‐acting antivirals
HCV
HIV
Immunodepression‐related infections
Issue DateJan-2019
PublisherJohn Wiley & Sons
CitationJournal of Viral Hepatitis 26(1): 48-54 (2019)
AbstractVaricella‐zoster virus and hepatitis B virus reactivations have been reported after starting interferon‐free direct‐acting antiviral agent (DAA ) combinations. HIV /HCV ‐coinfected patients could be a high‐risk group for the reactivation of latent infections. Because of these, we report the occurrence of severe infections after starting DAA regimens in HIV /HCV ‐coinfected patients. Individuals included in the HEPAVIR ‐DAA (NCT 02057003) cohort were selected if they had received all‐oral DAA combinations. A retrospective review of clinical events registered between the start of DAA s and 12 months after SVR 12 was carried out. Overall, 38 (4.5%) of 848 patients presented infections. The incidence (95% confidence interval) of infections was 4.6 (3.3‐6.3) cases per 100 person‐years. The median (Q1‐Q3) time to the infection since baseline was 23 (7.3‐33) weeks. Five (13%) of the patients with infections died; four of them had cirrhosis. The frequency of previous AIDS was 21 (54%) for patients with infections and 324 (40%) for those without infections (P = 0.084). The median (Q1‐Q3) nadir CD 4 cell count of individuals with and without infections was 75 (53‐178) and 144 (67‐255) cells/μL, respectively (P = 0.047). Immunodepression‐associated infections were observed in 9 (1.1%) patients. All of them had suppressed HIV replication with antiretroviral therapy. In conclusion, severe infections are relatively common among HIV /HCV ‐coinfected patients receiving all‐oral DAA combinations. Some unusual reactivations of latent infections in patients with suppressed HIV replication seem to be temporally linked with DAA use.
DescriptionHEPAVIR, GEHEP and RIS‐HEP07 study groups.
Publisher version (URL)https://doi.org/10.1111/jvh.13003
URIhttp://hdl.handle.net/10261/213397
DOIhttp://dx.doi.org/10.1111/jvh.13003
ISSN1352-0504
E-ISSN1365-2893
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.